Literature DB >> 19303605

Differences in retinal nerve fiber layer atrophy between multiple sclerosis subtypes.

Fiona Costello1, William Hodge, Y Irene Pan, Mark Freedman, Christine DeMeulemeester.   

Abstract

OBJECTIVES: To determine whether retinal nerve fiber layer (RNFL) atrophy in the afferent visual pathway may complement existing tools used to describe and characterize differences across MS subtypes.
METHODS: Optical coherence tomography-measured RNFL values were compared over two years in 35 patients (70 eyes) with optic neuritis (ON) as a clinically isolated syndrome (CIS); 39 patients (78 eyes) with relapsing remitting MS (RRMS); and 7 patients (14 eyes) with secondary progressive MS (SPMS).
RESULTS: RNFL comparisons involving eyes without ON yielded greater differences between MS subtypes than ON-affected eyes. Overall RNFL values in non-affected eyes were reduced in SPMS patients (83.4 microm), relative to CIS (101.2 microm) (p=0.0009), and RRMS patients (103.7 microm) (p=0.001); and temporal RNFL atrophy was greater in RRMS (64.4 microm) eyes as compared to CIS eyes (73.2 microm) (p=0.02). In ON-affected eyes, RNFL atrophy was greater in SPMS patients (39.5 microm) than CIS patients (58.1 microm) (p=0.03), and in RRMS patients (48.2 microm) relative to CIS patients (p=0.05). RNFL values did not change significantly for any MS subtype during the two-year duration of the study.
INTERPRETATION: RNFL thickness may represent a structural marker, which can help distinguish MS subtypes, because the extent of atrophy is commensurate with disease progression. RNFL comparisons between non-affected eyes revealed greater differences between CIS, RRMS, and SPMS patients relative to ON-affected eyes, because the impact of prior ON may supplant the effects of disease subtype.

Entities:  

Mesh:

Year:  2009        PMID: 19303605     DOI: 10.1016/j.jns.2009.02.354

Source DB:  PubMed          Journal:  J Neurol Sci        ISSN: 0022-510X            Impact factor:   3.181


  42 in total

Review 1.  Optical coherence tomography (OCT): imaging the visual pathway as a model for neurodegeneration.

Authors:  Kristin M Galetta; Peter A Calabresi; Elliot M Frohman; Laura J Balcer
Journal:  Neurotherapeutics       Date:  2011-01       Impact factor: 7.620

Review 2.  Imaging and photodynamic therapy: mechanisms, monitoring, and optimization.

Authors:  Jonathan P Celli; Bryan Q Spring; Imran Rizvi; Conor L Evans; Kimberley S Samkoe; Sarika Verma; Brian W Pogue; Tayyaba Hasan
Journal:  Chem Rev       Date:  2010-05-12       Impact factor: 60.622

3.  Anatomical and functional retinal changes in multiple sclerosis.

Authors:  G Cennamo; M R Romano; E C Vecchio; C Minervino; C Della Guardia; N Velotti; A Carotenuto; S Montella; G Orefice; G Cennamo
Journal:  Eye (Lond)       Date:  2015-12-18       Impact factor: 3.775

4.  Microcystic macular oedema in multiple sclerosis is associated with disease severity.

Authors:  Jeffrey M Gelfand; Rachel Nolan; Daniel M Schwartz; Jennifer Graves; Ari J Green
Journal:  Brain       Date:  2012-04-25       Impact factor: 13.501

5.  A preliminary longitudinal study of the retinal nerve fiber layer in progressive multiple sclerosis.

Authors:  Andrew P D Henderson; S A Trip; P G Schlottmann; D R Altmann; D F Garway-Heath; G T Plant; D H Miller
Journal:  J Neurol       Date:  2010-02-09       Impact factor: 4.849

6.  Damage of the lateral geniculate nucleus in MS: Assessing the missing node of the visual pathway.

Authors:  Athina Papadopoulou; Laura Gaetano; Armanda Pfister; Anna Altermatt; Charidimos Tsagkas; Felix Morency; Alexander U Brandt; Martin Hardmeier; Mallar M Chakravarty; Maxime Descoteaux; Ludwig Kappos; Till Sprenger; Stefano Magon
Journal:  Neurology       Date:  2019-04-10       Impact factor: 9.910

Review 7.  Optical coherence tomography in multiple sclerosis.

Authors:  Josefine Britze; Jette Lautrup Frederiksen
Journal:  Eye (Lond)       Date:  2018-02-02       Impact factor: 3.775

Review 8.  Evolution of Visual Outcomes in Clinical Trials for Multiple Sclerosis Disease-Modifying Therapies.

Authors:  Rachel C Nolan; Omar Akhand; John-Ross Rizzo; Steven L Galetta; Laura J Balcer
Journal:  J Neuroophthalmol       Date:  2018-06       Impact factor: 3.042

Review 9.  [Diagnosis and monitoring of multiple sclerosis: the value of optical coherence tomography].

Authors:  M Bock; F Paul; J Dörr
Journal:  Nervenarzt       Date:  2013-04       Impact factor: 1.214

10.  Longitudinal optical coherence tomography study of optic atrophy in secondary progressive multiple sclerosis: Results from a clinical trial cohort.

Authors:  Kimberly M Winges; Charles F Murchison; Dennis N Bourdette; Rebecca I Spain
Journal:  Mult Scler       Date:  2017-11-07       Impact factor: 6.312

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.